Royalty Pharma plc (RPRX)

Royalty Pharma Revenue

Royalty Pharma had revenue of $674.14M in the quarter ending June 30, 2026, with 16.50% growth. This brings the company's total for the last twelve months to $2.54B, up 10.01% year-over-year. In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth. That makes Royalty Pharma the 4,281st largest company in the world by revenue and 1,155th in the United States.

• Revenue (ttm): $2.54B
• Revenue Growth: +10.01%
• P/S Ratio: 15.23
• Revenue / Employee: $25,359,980
• Employees: 100
• Market Cap: 38.63B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Cystic Fibrosis Franchise 828.18M 34.8%
• Other Products 647.67M 27.2%
• Evrysdi 206.97M 8.7%
• Voranigo 154.42M 6.5%
• Trelegy 154.10M 6.5%
• Tremfya 152.94M 6.4%
• Other Royalty Income and 117.04M 4.9%
• Tysabri 116.88M 4.9%

Fiscal year ended Dec 31, 2025 See the full Royalty Pharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.38B	114.62M	5.06%
Dec 31, 2024	2.26B	-90.98M	-3.86%
Dec 31, 2023	2.35B	117.34M	5.24%
Dec 31, 2022	2.24B	-52.25M	-2.28%
Dec 31, 2021	2.29B	167.11M	7.87%
Dec 31, 2020	2.12B	308.10M	16.98%
Dec 31, 2019	1.81B	19.36M	1.08%
Dec 31, 2018	1.79B	196.96M	12.33%
Dec 31, 2017	1.60B	-	-

Data Source: Fiscal.ai Last updated: Aug 5, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error